Can Shimadzu become a player?

Will a new partnership with Change Healthcare help Shimadzu Medical Systems gain ground in the Interventional Vascular and/or Cardiac markets? At the Transcatheter Cardiovascular Therapeutics (TCT) 2018 Symposium in San Diego in September, Shimadzu featured the new Trinias C-12 Crossover system, which can perform both vascular and cardiac interventional procedures. The Trinias system is available in single or bi-plane, and in ceiling- or floor-mounted configuration. The system was released in 2014, but the MD Buyline database does not see quote activity for it.

Although Shimadzu offers a competitive product, the company has struggled over the years to promote and sell this system in the United States. On Sept. 25, Shimadzu announced a partnership with Change Healthcare by which Shimadzu will now offer Change Healthcare Cardiology Hemodynamic systems. Cardiovascular disease is a major problem in the United States and will likely be even more so over the years to come.

Extending Capabilities

Tim Stevener, director of cardiology with Shimadzu USA, observed of the new partnership: “We are proud to solidify a partnership with Change Healthcare, and extend the capabilities of their cardiology hemodynamics solution to achieve a shared initiative of providing healthcare organizations with solutions that help them meet their operational and quality initiatives.”

Shimadzu is hoping that the combination of the Trinias system and Change Healthcare’s Cardiology Hemodynamic systems will enable it to compete with the other vendors in the Interventional Vascular and/or Cardiology markets such as Canon, GE, Philips, and Siemens. The latter two, according to the MD Buyline database, are the big players in this market.


Jamie Dildy, Clinical Analyst

Jamie Dildy joined MD Buyline in 2009 with more than 10 years’ experience as an interventional radiology technologist.